INFU
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E, PEG, Graham Number
- P/E is lower than the healthcare sector average (32.84 vs 75.46)
- Price exceeds Intrinsic Value ($9.14)
- Price is more than double the Graham Number ($4.45)
Ref Growth rates
- Triple-digit earnings growth
- Strong track record of beating estimates (3/4 last quarters)
- Slow top-line revenue growth (7%)
Ref Historical trends
- Strong 1-year recovery (+106.1%)
- Poor 5-year performance (-55.2%)
Ref Altman Z-Score, Piotroski F-Score
- Piotroski F-Score of 8/9
- Low Debt/Equity
- Strong Current/Quick ratios
- Altman Z-Score not provided
Ref Yield, Payout
- No dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for INFU and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
Primary
|
-55.2% | +8.6% | +106.1% | -2.6% | +8.9% | -1.2% |
|
HITI
High Tide Inc.
Peer
|
-71.8% | +84.9% | +18.3% | -32.1% | -5.7% | +0.9% |
|
ANIK
Anika Therapeutics, Inc.
Peer
|
-62.2% | -47.2% | -6.6% | +63.8% | +38.5% | +0.6% |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
Peer
|
-100.0% | -99.8% | -4.1% | -27.7% | -4.4% | +10.5% |
|
OGI
Organigram Global Inc.
Peer
|
-84.9% | -32.0% | +46.1% | -22.4% | +7.0% | +9.3% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
INFU
InfuSystem Holdings, Inc.
|
NEUTRAL | $205.57M | 32.84 | 11.5% | 4.6% | $10.18 | |
|
HITI
High Tide Inc.
|
BEARISH | $204.8M | - | -39.7% | -7.4% | $2.33 | Compare |
|
ANIK
Anika Therapeutics, Inc.
|
BEARISH | $204.78M | - | -6.7% | -9.6% | $14.2 | Compare |
|
TNXP
Tonix Pharmaceuticals Holding Corp.
|
BEARISH | $203.71M | - | -64.5% | -% | $14.34 | Compare |
|
OGI
Organigram Global Inc.
|
BEARISH | $209.6M | 13.82 | 4.6% | 6.5% | $1.52 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | STEELE BARRY G. | Chief Financial Officer | Purchase | 2,064 | $18,906 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
INFU relies substantially on third-party reimbursements from private insurers and government agencies for its revenues related to continuous infusion equipment and supplies. The company faces significant risks from potential reductions in allowable fees, payment delays, and systemic changes in the healthcare reimbursement landscape that could materially adversely affect its financial condition.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning INFU from our newsroom.